OTCMKTS:REMI Remedent (REMI) Stock Price, News & Analysis $0.05 0.00 (0.00%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsSEC Filings About Remedent Stock (OTCMKTS:REMI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Remedent alerts:Sign Up Key Stats Today's Range$0.05▼$0.0550-Day Range$0.05▼$0.0652-Week Range$0.00▼$0.15Volume5,000 shsAverage Volume2 shsMarket Capitalization$1 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewRemedent, Inc. researches, designs, develops, manufactures, and distributes oral care and cosmetic dentistry products in the United States and internationally. It primarily provides professional veneers and teeth whitening products for professional and over-the-counter use. The company also offers River8, a prefab veneer that enables the dentist to find the right combination of teeth for a patient with minor reshaping. In addition, it provides GlamSmile veneers, which are ultra-thin claddings attached to the front of the patient's teeth. Further, the company offers SmileMe Mirror, an integrated marketing concept for the dental practice that enables dentists to offer smile consultation in approximately 10 minutes; SmileSketch, a simulation software to make a sketch of what the patient could look like; and various Treatment Pages to explain the benefits of certain treatments, as well as Condor, an intra-oral 3D scanner. Additionally, it provides dental implant solutions and treatment concepts. The company sells its products through internal sales force and third party distributors. Remedent, Inc. was incorporated in 1986 and is headquartered in Ghent, Belgium.Read More… Buffett Dumps $982 Million in BofA Stock—What Does He Know? (Ad)Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Receive REMI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Remedent and its competitors with MarketBeat's FREE daily newsletter. Email Address REMI Stock News HeadlinesEx-Chelsea striker looks like completely new person just one year after retirementAugust 28, 2024 | mirror.co.ukREMYY Rémy Cointreau SAApril 24, 2024 | seekingalpha.comDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.November 23, 2024 | DTI (Ad)Peterson RemyFebruary 15, 2024 | health.usnews.comRemi Wolf Returns with New Single “Prescription,” Inspired by Phone Call with Boots Riley: StreamJune 2, 2023 | yahoo.comLove Island star Remi Lambert claims he was assaulted by one of Jacques O'Neill's friendsMarch 22, 2023 | mirror.co.ukWhere is Remi Adeleke and who is Chris Oliver from SAS: Who Dares Wins?January 25, 2023 | uk.news.yahoo.comRemedent, Inc. (REMI)August 22, 2022 | finance.yahoo.comSee More Headlines REMI Stock Analysis - Frequently Asked Questions How have REMI shares performed this year? Remedent's stock was trading at $0.0970 at the beginning of the year. Since then, REMI stock has decreased by 48.5% and is now trading at $0.05. View the best growth stocks for 2024 here. How do I buy shares of Remedent? Shares of REMI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Remedent own? Based on aggregate information from My MarketBeat watchlists, some other companies that Remedent investors own include AbbVie (ABBV), CoStar Group (CSGP), Enterprise Products Partners (EPD), Kellanova (K), Kandi Technologies Group (KNDI), MKS Instruments (MKSI) and M&T Bank (MTB). Company Calendar Today11/23/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Dental equipment & supplies Sub-IndustryN/A Current SymbolOTCMKTS:REMI CUSIPN/A CIK1078037 Webwww.remedent.com Phone(329) 241-5880Fax329-241-5899Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-270,000.00 Net Margins-25.56% Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$990,000.00 Price / Sales1.01 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares20,000,000Free FloatN/AMarket Cap$1 million OptionableNot Optionable Beta-0.01 Social Links A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (OTCMKTS:REMI) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Remedent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Remedent With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.